KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer | Zendy

Julie N. Graff | Zendy; Li Liang | Zendy; Jeri Kim | Zendy; Arnulf Stenzl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer

Author(s) -

Julie N. Graff,

Li Liang,

Jeri Kim,

Arnulf Stenzl

Publication year - 2021

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2020-1008

Subject(s) - enzalutamide , medicine , prostate cancer , pembrolizumab , oncology , cancer , immunotherapy , androgen receptor

Current treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) are noncurative, and median survival upon development of mCRPC is approximately 3 years. The novel hormonal agent enzalutamide has an established role in the mCRPC treatment paradigm, and emerging evidence suggests potential synergism with enzalutamide and the PD-1 inhibitor pembrolizumab in men with mCRPC. Here, we describe the design and rationale for the multicenter, randomized, double-blind, Phase III KEYNOTE-641 study, which will be conducted to compare the efficacy and safety of pembrolizumab plus enzalutamide with that of enzalutamide plus placebo in mCRPC. Clinical trial registration: NCT03834493 ( ClinicalTrials.gov )

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research